Clinical trial
Irofulven in Treating Patients With Recurrent or Metastatic Gastric Cancer
NCT00062257 · Cancer Therapeutics Research Group, Other · Completed
Key facts
| NCT number | NCT00062257 |
|---|---|
| Title | Irofulven in Treating Patients With Recurrent or Metastatic Gastric Cancer |
| Official title | A Phase II Study of Irofulven as First Line Therapy in Recurrent or Metastatic Gastric Cancer |
| Lead sponsor | Cancer Therapeutics Research Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastric Cancer |
| Intervention type | Drug |
| Interventions | irofulven |
| Start date | Jun 1, 2003 |
| Completion | Sep 1, 2006 |
| First posted | Jun 6, 2003 |
| Last update posted | May 15, 2013 |
| Countries | Australia, Hong Kong, Singapore, South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: